NAcGM3/VSSP/Montanide ISA

2 trials

Sponsors

Center of Molecular Immunology(CIM), Center of Molecular Immunology (CIM)

Conditions

HIV/AIDSMetastatic Breast Cancer

Phase 2

NGcGM3/VSSP/Montanide ISA 51 vaccine in metastatic breast cancer. Phase II

Active, not recruitingRPCEC00000068

Center of Molecular Immunology (CIM)Metastatic Breast Cancer

Start: 2002-08-27Target: 80Updated: 2026-03-30

NAcGM3/VSSP/Montanide ISA 51 formulation in HIV, phase II.

RecruitingRPCEC00000015

Center of Molecular Immunology(CIM)HIV/AIDS

Start: 2008-02-21Target: 118Updated: 2026-03-30